An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.

PubWeight™: 2.14‹?› | Rank: Top 2%

🔗 View Article (PMID 21251615)

Published in Cancer Cell on January 18, 2011


Nicholas S Wilson1, Becky Yang, Annie Yang, Stefanie Loeser, Scot Marsters, David Lawrence, Yun Li, Robert Pitti, Klara Totpal, Sharon Yee, Sarajane Ross, Jean-Michel Vernes, Yanmei Lu, Cam Adams, Rienk Offringa, Bob Kelley, Sarah Hymowitz, Dylan Daniel, Gloria Meng, Avi Ashkenazi

Author Affiliations

1: Department of Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.

Articles citing this

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science (2011) 2.63

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96

Getting TRAIL back on track for cancer therapy. Cell Death Differ (2014) 1.86

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov (2012) 1.62

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53

Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD. Blood (2015) 1.46

Antibody-based immunotherapy of cancer. Cell (2012) 1.35

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther (2012) 1.24

Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest (2015) 1.24

Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut (2012) 1.22

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol (2013) 1.18

Mechanisms of action of CD20 antibodies. Am J Cancer Res (2012) 1.15

The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol (2012) 1.11

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc Natl Acad Sci U S A (2012) 1.11

Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun (2012) 1.05

Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs (2011) 1.04

Death receptor-ligand systems in cancer, cell death, and inflammation. Cold Spring Harb Perspect Biol (2013) 1.03

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol Res (2014) 0.97

Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc Natl Acad Sci U S A (2013) 0.96

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res (2011) 0.96

A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle (2012) 0.94

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem (2012) 0.93

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng Des Sel (2013) 0.92

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem (2013) 0.91

H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. J Immunol (2015) 0.91

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies? Oncoimmunology (2012) 0.91

Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies. Mol Pharmacol (2014) 0.89

Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med (2014) 0.89

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol (2012) 0.89

Onto better TRAILs for cancer treatment. Cell Death Differ (2016) 0.88

TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene (2014) 0.88

Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci U S A (2015) 0.88

Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation. Cell Death Dis (2015) 0.86

Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ (2013) 0.85

Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance. Am J Clin Exp Immunol (2013) 0.84

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med (2013) 0.84

Principles of antibody-mediated TNF receptor activation. Cell Death Differ (2015) 0.84

Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction. MAbs (2014) 0.83

The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent. Biochim Biophys Acta (2011) 0.82

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis (2014) 0.81

Design of CD40 agonists and their use in growing B cells for cancer immunotherapy. Int Rev Immunol (2012) 0.81

Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine (2013) 0.81

Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80

Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther (2015) 0.80

Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag. J Virol (2013) 0.79

Targeting and utilizing primary tumors as live vaccines: changing strategies. Cell Mol Immunol (2011) 0.79

Influence of immunoglobulin isotype on therapeutic antibody function. Blood (2016) 0.78

Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells. Methods (2015) 0.78

CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis (2013) 0.78

Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma. ISRN Oncol (2012) 0.77

Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. Mol Ther (2014) 0.76

The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat (2016) 0.76

The role of Fc-FcγR interactions in the anti-tumor activity of therapeutic antibodies. Immunol Cell Biol (2016) 0.75

Fc engineering approaches to enhance the agonism and effector functions of an anti-OX40 antibody. J Biol Chem (2016) 0.75

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother (2016) 0.75

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors. MAbs (2014) 0.75

hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. Cell Death Discov (2016) 0.75

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma. Br J Cancer (2015) 0.75

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking. Oncoimmunology (2014) 0.75

Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death. Mol Cancer Ther (2015) 0.75

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? Expert Opin Biol Ther (2016) 0.75

DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo. J Exp Med (2017) 0.75

Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB. J Clin Immunol (2016) 0.75

A potent human neutralizing antibody Fc-dependently reduces established HBV infections. Elife (2017) 0.75

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma. Cancer Med (2017) 0.75

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization. MAbs (2017) 0.75

Articles by these authors

A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09

A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science (2007) 43.16

Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06

Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83

Food security: the challenge of feeding 9 billion people. Science (2010) 22.51

METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics (2010) 21.21

Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66

Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet (2011) 18.88

New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89

Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27

Widespread RNA and DNA sequence differences in the human transcriptome. Science (2011) 11.45

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45

A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature (2012) 8.10

An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94

Genotype-imputation accuracy across worldwide human populations. Am J Hum Genet (2009) 7.28

Adaptive particle swarm optimization. IEEE Trans Syst Man Cybern B Cybern (2009) 6.47

Regions of strong coupling between soil moisture and precipitation. Science (2004) 5.96

The genome of a songbird. Nature (2010) 5.90

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell (2009) 5.55

Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet (2008) 5.55

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54

Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci U S A (2004) 5.15

CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med (2013) 5.04

Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature (2012) 4.95

Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nat Genet (2010) 4.69

Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet (2008) 4.69

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56

CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet (2006) 4.51

Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet (2011) 4.50

Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis (2004) 4.29

Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10

Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets. Genome Res (2008) 4.08

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med (2007) 3.99

p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75

Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol (2009) 3.63

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54

Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol (2005) 3.54

Extending rare-variant testing strategies: analysis of noncoding sequence and imputed genotypes. Am J Hum Genet (2010) 3.47

A multinational cohort study of in-center daily hemodialysis and patient survival. Kidney Int (2012) 3.47

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31

REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell (2002) 3.29

Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals. Am J Hum Genet (2010) 3.28

CEP152 is a genome maintenance protein disrupted in Seckel syndrome. Nat Genet (2010) 3.25

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18

Left atrial and right ventricular myxoma: an uncommon presentation of a rare tumour. Interact Cardiovasc Thorac Surg (2011) 3.17

Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09

A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00

Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer (2008) 2.98

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95

Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90

Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev (2003) 2.84

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81

Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76

Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am J Hum Genet (2011) 2.69

Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat Genet (2010) 2.66

Tumor necrosis factor: an apoptosis JuNKie? Cell (2004) 2.64

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64

Temperature drift compensation for Hemispherical Resonator Gyro based on natural frequency. Sensors (Basel) (2012) 2.62

Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA (2004) 2.55

Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33

Force to rebalance control of HRG and suppression of its errors on the basis of FPGA. Sensors (Basel) (2011) 2.22

Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet (2009) 2.19

A comparison of approaches to account for uncertainty in analysis of imputed genotypes. Genet Epidemiol (2011) 2.19

Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. Br J Psychiatry (2011) 2.17

Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17

Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs. Kidney Int (2013) 2.14

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14

NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-α feedforward signaling. Cell (2011) 2.13

The effect of recalling paracetamol on hospital admissions for poisoning in Western Australia. Med J Aust (2003) 2.11

TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest (2012) 2.10

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 2.10

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res (2008) 2.06

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther (2012) 2.03

Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes (2008) 2.01

Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet (2012) 2.00